By Mill Chart
Last update: Sep 16, 2025
In the world of growth investing, combining technical strength with fundamental momentum often yields promising candidates. One approach gaining traction is the integration of Mark Minervini’s Trend Template with high growth momentum (HGM) screening. This dual-lens strategy identifies stocks not only in strong technical uptrends but also showing accelerating earnings, sales, and profitability, key drivers of sustained outperformance. By filtering for stocks that meet Minervini’s strict trend criteria and have a high HGM rating (typically 4 or above), investors can pinpoint companies with both price momentum and fundamental growth catalysts.
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) appears as a notable example of this methodology, showing alignment with both technical and growth-oriented parameters.
Minervini’s Trend Template emphasizes stocks in clear stage 2 uptrends, characterized by specific moving average alignments, price action relative to highs, and strong relative strength. ARQT satisfies these conditions with notable consistency:
These technical traits are critical because they help filter out laggards and prioritize equities with institutional support and trend continuity, reducing downside risk while participating in upward moves.
Beyond technicals, ARQT exhibits explosive growth in key fundamental metrics, aligning with the high growth momentum screen:
These fundamentals are vital for high-growth investors because they signal a company’s capacity to expand rapidly, exceed expectations, and potentially justify higher valuations through sustained execution.
Operating in the biotechnology industry, ARQT focuses on dermatological treatments, with its lead product ZORYVE gaining traction for plaque psoriasis and atopic dermatitis. The company’s product pipeline and commercial execution appear to be key catalysts, aligning with Minervini’s emphasis on fundamental “superperformance” driven by new products or market expansions. The industry’s innovation pace and ARQT’s recent commercial launches provide a backdrop for continued growth, contingent on successful execution and market penetration.
According to ChartMill’s technical report, ARQT has a perfect technical rating of 10/10, reflecting exceptional trend health, while its setup rating of 7/10 indicates a consolidation pattern offering a potential entry point. Key takeaways include:
For a detailed technical breakdown, review the full technical analysis report here.
ARCUTIS BIOTHERAPEUTICS INC represents a notable case where Minervini’s trend-driven framework converges with high-growth fundamental dynamics. Its technical posture confirms a strong uptrend with healthy relative strength, while its financial metrics reveal rapid acceleration in earnings, sales, and analyst optimism. For investors seeking growth stocks with technical confirmation, ARQT offers a balanced profile of momentum and potential.
To explore more stocks that fit this High Growth Momentum + Trend Template screen, click here for the full screening results.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All investments involve risk, and readers should conduct their own research and consult with a qualified financial advisor before making investment decisions.
17.38
-0.33 (-1.86%)
Find more stocks in the Stock Screener